PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
32443652-4	2020	COE-7, and COE-22 were also active against MAO-B, both had an IC50 value of 0.028 microM, which was 67 and 1.5 times lower than those of clorgyline and lazabemide, respectively.	lazabemide	152-162	monoamine oxidase B	Homo sapiens	43-48
29195801-5	2018	The Ki value of F1 is the lowest among the values of chalcone derivatives and furthermore lower than that (0.0079 muM) of the reversible MAO-B inhibitor, lazabemide, a marketed drug.	lazabemide	154-164	monoamine oxidase B	Homo sapiens	137-142
31550216-11	2019	Inhibitions of hMAO-B by L3 or L4 were recovered to the level of the reversible reference (lazabemide), and were competitive with Ki values of 0.0030 +- 0.0002 and 0.0046 +- 0.0005 muM, respectively.	lazabemide	91-101	monoamine oxidase B	Homo sapiens	15-21
30143367-1	2018	In the studied a series novel of lazabemide derivatives were designed, synthesized and evaluated as inhibitors of monoamine oxidase (MAO-A or MAO-B).	lazabemide	33-43	monoamine oxidase A	Homo sapiens	133-138
30143367-1	2018	In the studied a series novel of lazabemide derivatives were designed, synthesized and evaluated as inhibitors of monoamine oxidase (MAO-A or MAO-B).	lazabemide	33-43	monoamine oxidase B	Homo sapiens	142-147
29958546-7	2018	In in vitro autoradiography, specific THK5351 binding was detected in the area of antemortem [18F]THK5351 retention, and binding was blocked completely by a reversible selective MAO-B inhibitor, lazabemide, in brain samples from these patients.	lazabemide	195-205	monoamine oxidase B	Homo sapiens	178-183
29186917-5	2017	Lazabemide is a monoamine oxidase (MAO)-B inhibitor, a class of compounds that slows the depletion of dopamine stores in Parkinson"s disease and elevates dopamine levels produced by exogenously administered l-dopa.	lazabemide	0-10	monoamine oxidase B	Mus musculus	16-41
17570647-0	2008	Specific binding of [3H]Ro 19-6327 (lazabemide) to monoamine oxidase B is increased in frontal cortex of suicide victims after controlling for age at death.	lazabemide	36-46	monoamine oxidase B	Homo sapiens	51-70
17570647-3	2008	We have evaluated the association of MAO-B density (assessed by [3H]Ro 19-6327 - lazabemide - binding) with type of death (suicide victims vs non-suicide controls) after controlling for age at death.	lazabemide	81-91	monoamine oxidase B	Homo sapiens	37-42
15545290-6	2004	In contrast, the reversible MAO-A inhibitor moclobemide (2.5-10 mg kg(-1)) and the reversible MAO-B inhibitor lazabemide (2.5-10 mg kg(-1)) failed to instigate significant rotational behaviour compared to vehicle.	lazabemide	110-120	monoamine oxidase B	Rattus norvegicus	94-99
12818349-3	2003	We thought worthwide to evaluate the effect of Ro 41-1049 and lazabemide, both members of a class of highly selective, mechanism-based and reversible inhibitors for MAO-A and MAO B, respectively on the metabolization of beta-PEA by the rat heart.	lazabemide	62-72	monoamine oxidase A	Rattus norvegicus	165-170
12818349-3	2003	We thought worthwide to evaluate the effect of Ro 41-1049 and lazabemide, both members of a class of highly selective, mechanism-based and reversible inhibitors for MAO-A and MAO B, respectively on the metabolization of beta-PEA by the rat heart.	lazabemide	62-72	monoamine oxidase B	Rattus norvegicus	175-180
12818349-6	2003	Unexpectedly, the selective MAO-A inhibitor Ro 41-1049 was by far the most potent inhibitor of beta-PEA (20 microM) deamination in the rat heart, while clorgyline, another MAO A inhibitor, and lazabemide, a MAO B inhibitor, had intermediate efficacy; selegiline was found unable to inhibit deamination of beta-PEA.	lazabemide	193-203	monoamine oxidase A	Rattus norvegicus	28-33
11673765-3	2001	RESULTS: In rat brain, harmaline and lazabemide showed potent and selective inhibition of MAO(A) and MAO(B), their respective target enzymes, with IC(50) values of 2.3 and 18 nM.	lazabemide	37-47	monoamine oxidase A	Rattus norvegicus	90-93
12359039-0	2002	Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	36-55
12359039-5	2002	AIMS: To assess whether lazabemide, a reversible selective MAOB inhibitor, promotes smoking cessation.	lazabemide	24-34	monoamine oxidase B	Homo sapiens	59-63
11956949-1	2002	The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and -B inhibitors, clorgyline and lazabemide.	lazabemide	315-325	amine oxidase, copper containing 3	Rattus norvegicus	47-84
11956949-1	2002	The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and -B inhibitors, clorgyline and lazabemide.	lazabemide	315-325	amine oxidase, copper containing 3	Rattus norvegicus	98-102
11956949-1	2002	The specific activity and kinetic behaviour of semicarbazide-sensitive amine oxidase (EC 1.4.3.6; SSAO) towards benzylamine, in the rat heart, is affected by in vivo treatment with the non-selective monoamine oxidase (MAO) inhibitor tranylcypromine, but not by the selective MAO-A and -B inhibitors, clorgyline and lazabemide.	lazabemide	315-325	monoamine oxidase A	Rattus norvegicus	199-216
11673765-3	2001	RESULTS: In rat brain, harmaline and lazabemide showed potent and selective inhibition of MAO(A) and MAO(B), their respective target enzymes, with IC(50) values of 2.3 and 18 nM.	lazabemide	37-47	monoamine oxidase B	Rattus norvegicus	101-107
10408736-10	1999	Free radical scavengers/antioxidants such as idebenone, and selective prevention MAO-B inhibitors such as lazabemide are well tolerated, but require additional studies in order to demonstrate preventative effects.	lazabemide	106-116	monoamine oxidase B	Homo sapiens	81-86
10626094-0	1999	Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson"s disease.	lazabemide	16-26	monoamine oxidase B	Homo sapiens	46-51
11129505-0	2000	MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats.	lazabemide	51-61	monoamine oxidase B	Rattus norvegicus	0-5
10927030-0	2000	Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.	lazabemide	58-68	monoamine oxidase B	Homo sapiens	28-47
10927030-3	2000	In this study, the intrinsic antioxidant activity of lazabemide, a potent and reversible inhibitor of monoamine oxidase B (MAO-B), was tested in a membrane-based model of oxidative stress.	lazabemide	53-63	monoamine oxidase B	Homo sapiens	102-121
10927030-3	2000	In this study, the intrinsic antioxidant activity of lazabemide, a potent and reversible inhibitor of monoamine oxidase B (MAO-B), was tested in a membrane-based model of oxidative stress.	lazabemide	53-63	monoamine oxidase B	Homo sapiens	123-128
10688633-5	2000	These data suggested that the inhibitory effect of these compounds on MAO-B activity involved a secondary interaction with the enzyme domain recognizing the inhibitor Ro 19-6327 and does not involve interaction with the IBD.	lazabemide	167-177	monoamine oxidase B	Homo sapiens	70-75
9489509-1	1998	The present study reports on the presence of type A and B monoamine oxidase (MAO) activity and their sensitivity to selective MAO-A and MAO-B inhibition by Ro 41-1049 and lazabemide, respectively, in homogenates of isolated rat renal tubules.	lazabemide	171-181	monoamine oxidase A	Rattus norvegicus	77-80
9489509-1	1998	The present study reports on the presence of type A and B monoamine oxidase (MAO) activity and their sensitivity to selective MAO-A and MAO-B inhibition by Ro 41-1049 and lazabemide, respectively, in homogenates of isolated rat renal tubules.	lazabemide	171-181	monoamine oxidase A	Rattus norvegicus	126-131
9489509-1	1998	The present study reports on the presence of type A and B monoamine oxidase (MAO) activity and their sensitivity to selective MAO-A and MAO-B inhibition by Ro 41-1049 and lazabemide, respectively, in homogenates of isolated rat renal tubules.	lazabemide	171-181	monoamine oxidase B	Rattus norvegicus	136-141
9466361-1	1998	The reversible and highly selective monoamine oxidase B (MAO-B) inhibitor Ro 19-6327, a picolinic acid derivative, was selected for the development of new radiopharmaceuticals, whereby in place of Cl either 123I or 18F was introduced.	lazabemide	74-84	monoamine oxidase B	Homo sapiens	36-55
9466361-1	1998	The reversible and highly selective monoamine oxidase B (MAO-B) inhibitor Ro 19-6327, a picolinic acid derivative, was selected for the development of new radiopharmaceuticals, whereby in place of Cl either 123I or 18F was introduced.	lazabemide	74-84	monoamine oxidase B	Homo sapiens	57-62
9444560-7	1997	However, in conjunction with COMT inhibition, 10 mg/kg of the MAO-B inhibitor, Ro 19-6327, significantly affected both the number and duration of turning behavior.	lazabemide	79-89	catechol-O-methyltransferase	Rattus norvegicus	29-33
9394121-2	1997	The density of MAO-B sites was quantified by the specific binding of the selective inhibitor [3H]Ro 19-6327 (lazabemide) (8 nM) to cortical membranes.	lazabemide	97-107	monoamine oxidase B	Homo sapiens	15-20
9394121-2	1997	The density of MAO-B sites was quantified by the specific binding of the selective inhibitor [3H]Ro 19-6327 (lazabemide) (8 nM) to cortical membranes.	lazabemide	109-119	monoamine oxidase B	Homo sapiens	15-20
9056051-0	1997	Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.	lazabemide	90-100	monoamine oxidase B	Homo sapiens	74-79
9056051-1	1997	AIMS: The objectives of this study were to assess the tolerability, pharmacokinetics and pharmacodynamics of the reversible monoamine oxidase B (MAO-B) inhibitor, lazabemide, in healthy subjects.	lazabemide	163-173	monoamine oxidase B	Homo sapiens	124-143
9056051-1	1997	AIMS: The objectives of this study were to assess the tolerability, pharmacokinetics and pharmacodynamics of the reversible monoamine oxidase B (MAO-B) inhibitor, lazabemide, in healthy subjects.	lazabemide	163-173	monoamine oxidase B	Homo sapiens	145-150
9056051-10	1997	Lazabemide caused a rapid and reversible inhibition of MAO-B activity in platelets.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	55-60
9116589-5	1997	The density of brain MAO-B sites labeled by [3H]Ro 19-6327 (lazabemide) in suicides was no different to that in age-matched controls.	lazabemide	60-70	monoamine oxidase B	Homo sapiens	21-26
9444560-7	1997	However, in conjunction with COMT inhibition, 10 mg/kg of the MAO-B inhibitor, Ro 19-6327, significantly affected both the number and duration of turning behavior.	lazabemide	79-89	monoamine oxidase B	Rattus norvegicus	62-67
7816197-4	1994	Using tritiated monoamine oxidase inhibitors (Ro41-1049 and lazabemide)--as high affinity substrates selective for monoamine oxidases A and B, respectively--it was found that monoamine oxidase B activity increased up to three-fold exclusively in temporal, parietal and frontal cortices of Alzheimer disease cases compared with controls.	lazabemide	60-70	monoamine oxidase A	Homo sapiens	115-141
8665924-0	1996	Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis.	lazabemide	123-133	monoamine oxidase B	Homo sapiens	53-72
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	68-78	monoamine oxidase B	Rattus norvegicus	39-58
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	68-78	monoamine oxidase B	Rattus norvegicus	60-65
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	68-78	monoamine oxidase B	Rattus norvegicus	226-231
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	68-78	monoamine oxidase B	Rattus norvegicus	226-231
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	238-248	monoamine oxidase B	Rattus norvegicus	39-58
7632769-1	1994	The selective, reversible inhibitor of monoamine oxidase B (MAO-B), Ro 19-6327 (Lazabamide) N-aminoethyl-5-chloro-picolinamide, inhibits the enzyme with an initial competitive phase, followed by a time-dependent inhibition of MAO-B; i.e. Ro 19-6327 is a substrate for MAO-B, and after its oxidation it is activated into an intermediate form which remains tightly bound to the enzyme"s active site.	lazabemide	238-248	monoamine oxidase B	Rattus norvegicus	60-65
8665924-2	1996	The pseudosubstrate inhibitor N-[2-aminoethyl]-5-chloro-2-pyridine carboxamide HCl (lazabemide) can be irreversibly linked to MAO-B by reduction of the enzyme-inhibitor complex with NaBH(3)CN.	lazabemide	84-94	monoamine oxidase B	Homo sapiens	126-131
7605351-0	1995	In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.	lazabemide	98-108	monoamine oxidase B	Rattus norvegicus	67-86
7605351-1	1995	To investigate whether the reversible monoamine oxidase-B (MAO-B) inhibitors lazabemide and Ro 16-6491 have any additional effect on monoamine uptake and release, in vitro experiments were performed on rat forebrain synaptosomes and blood platelets.	lazabemide	77-87	monoamine oxidase B	Rattus norvegicus	38-57
7605351-1	1995	To investigate whether the reversible monoamine oxidase-B (MAO-B) inhibitors lazabemide and Ro 16-6491 have any additional effect on monoamine uptake and release, in vitro experiments were performed on rat forebrain synaptosomes and blood platelets.	lazabemide	77-87	monoamine oxidase B	Rattus norvegicus	59-64
7605351-10	1995	The data indicate that the reversible MAO-B inhibitors lazabemide and Ro 16-6491 at relatively high concentrations possess amine uptake-inhibiting properties.	lazabemide	55-65	monoamine oxidase B	Rattus norvegicus	38-43
7601156-5	1995	Whereas exchange of the ADP-binding sequence did not modify the catalytic properties of either MAO isoforms, chimeras with increasing length of the NH2-terminus of MAO-A (up to residue 256) showed a marked decrease in affinity towards the MAO-B substrate phenylethylamine and the inhibitor N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide .	lazabemide	290-338	monoamine oxidase A	Homo sapiens	164-169
7601156-5	1995	Whereas exchange of the ADP-binding sequence did not modify the catalytic properties of either MAO isoforms, chimeras with increasing length of the NH2-terminus of MAO-A (up to residue 256) showed a marked decrease in affinity towards the MAO-B substrate phenylethylamine and the inhibitor N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide .	lazabemide	290-338	monoamine oxidase B	Homo sapiens	239-244
7568334-1	1995	The effects of clorgyline, the MAO-A inhibitor, and lazabemide, the MAO-B inhibitor, on the levels of the hydroxyl radicals appearing in the cerebral ventricles of mice during brain ischemia/reperfusion were examined by using a salicylate trapping method.	lazabemide	52-62	monoamine oxidase B	Mus musculus	68-73
7816197-4	1994	Using tritiated monoamine oxidase inhibitors (Ro41-1049 and lazabemide)--as high affinity substrates selective for monoamine oxidases A and B, respectively--it was found that monoamine oxidase B activity increased up to three-fold exclusively in temporal, parietal and frontal cortices of Alzheimer disease cases compared with controls.	lazabemide	60-70	monoamine oxidase B	Homo sapiens	175-194
7816197-11	1994	Lazabemide, a selective reversible monoamine oxidase B inhibitor, is currently under clinical evaluation for the treatment of Parkinson"s and Alzheimer"s diseases.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	35-54
8413955-0	1993	Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson"s disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.	lazabemide	134-144	monoamine oxidase B	Homo sapiens	0-19
7917773-0	1994	Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.	lazabemide	20-30	monoamine oxidase B	Homo sapiens	72-91
7917773-2	1994	The inhibition of monoamine oxidase B (MAO-B) by lazabemide was measured in platelets collected from 35 young (19-36 years) and 40 older (60-78 years) healthy volunteers after single (100-300 mg) and multiple (100-350 mg twice daily) oral doses respectively.	lazabemide	49-59	monoamine oxidase B	Homo sapiens	18-37
7917773-2	1994	The inhibition of monoamine oxidase B (MAO-B) by lazabemide was measured in platelets collected from 35 young (19-36 years) and 40 older (60-78 years) healthy volunteers after single (100-300 mg) and multiple (100-350 mg twice daily) oral doses respectively.	lazabemide	49-59	monoamine oxidase B	Homo sapiens	39-44
7936114-7	1994	Irreversible and reversible MAO-B inhibitors, however, such as pargyline, aliphatic N-methylpropargylamines, Ro 19-6327 and MDL-72974A and MAO-A inhibitor moclobemide do not possess any appreciable inhibitory effects on dopamine uptake.	lazabemide	109-119	monoamine oxidase B	Rattus norvegicus	28-33
8155011-2	1994	BACKGROUND: Lazabemide (Ro 19-6327) is a short-acting, reversible, highly selective inhibitor of monoamine oxidase type B, that, unlike selegiline (deprenyl), is not metabolized to active compounds.	lazabemide	12-22	monoamine oxidase B	Homo sapiens	97-121
8155011-2	1994	BACKGROUND: Lazabemide (Ro 19-6327) is a short-acting, reversible, highly selective inhibitor of monoamine oxidase type B, that, unlike selegiline (deprenyl), is not metabolized to active compounds.	lazabemide	24-34	monoamine oxidase B	Homo sapiens	97-121
8155011-11	1994	CONCLUSIONS: The overall safety of lazabemide observed in this short-term study justifies further long-term investigations to determine if this monoamine oxidase type B inhibitor is a useful adjuvant to levodopa therapy in Parkinson"s disease.	lazabemide	35-45	monoamine oxidase B	Homo sapiens	144-168
7952273-11	1994	Moreover, enzyme radioautography with [3H]Ro 41-1049 revealed that SR 95531 has a significant affinity for MAO-A (IC50 values were 10(-5) and 4 x 10(-6) M in the LC and dentate gyrus respectively) but not for MAO-B ([3H]lazabemide binding).	lazabemide	220-230	monoamine oxidase A	Homo sapiens	107-112
7931245-0	1994	Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.	lazabemide	0-10	monoamine oxidase B	Rattus norvegicus	59-64
7931245-0	1994	Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.	lazabemide	12-22	monoamine oxidase B	Rattus norvegicus	59-64
8413955-0	1993	Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson"s disease: the degree and reversibility of human brain MAO B inhibition by Ro 19 6327.	lazabemide	134-144	monoamine oxidase B	Homo sapiens	114-119
8413955-2	1993	Ro 19 6327 is a highly selective inhibitor of MAO B currently under clinical investigation.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	46-51
8413955-3	1993	We used positron emission tomography (PET) and the MAO B tracer [11C]L-deprenyl to determine the degree and reversibility of human brain MAO B inhibition by Ro 19 6327 in six early Parkinson"s disease patients who were treated with different doses of Ro 19 6327 (25 mg [n = 3], 50 mg [n = 2], and 100 mg [n = 1]; 0.34 to 1.4 mg/kg) every 12 hours for 1 week.	lazabemide	157-167	monoamine oxidase B	Homo sapiens	137-142
8413955-7	1993	Thus, 0.4 mg/kg or greater of Ro 19 6327 given every 12 hours is the minimum dose necessary to provide > 90% inhibition of brain MAO B in patients with early PD.	lazabemide	30-40	monoamine oxidase B	Homo sapiens	129-134
8395564-5	1993	In an age-selected group (range, 10-89 years), the density of monoamine oxidase (MAO)-B sites labeled by [3H]Ro 19-6327 (lazabemide) also showed a positive correlation with age (r = 0.80; p < 0.005).	lazabemide	121-131	monoamine oxidase B	Homo sapiens	62-87
8374913-1	1993	Selegiline (deprenyl) and lazabemide (Ro 19-6327) are inhibitors of monoamine oxidase-B but differ in several other pharmacological properties.	lazabemide	26-36	monoamine oxidase B	Homo sapiens	68-87
8374913-1	1993	Selegiline (deprenyl) and lazabemide (Ro 19-6327) are inhibitors of monoamine oxidase-B but differ in several other pharmacological properties.	lazabemide	38-48	monoamine oxidase B	Homo sapiens	68-87
8321428-0	1993	A selective MAOB inhibitor Ro19-6327 potentiates the effects of levodopa on parkinsonism induced by MPTP in the common marmoset.	lazabemide	27-36	amine oxidase [flavin-containing] B	Callithrix jacchus	12-16
8489205-3	1993	Lazabemide (RO19-6327) is a short-acting, reversible, highly selective inhibitor of monoamine oxidase type B which, unlike deprenyl, is not metabolized to active compounds.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	84-108
8489205-3	1993	Lazabemide (RO19-6327) is a short-acting, reversible, highly selective inhibitor of monoamine oxidase type B which, unlike deprenyl, is not metabolized to active compounds.	lazabemide	12-21	monoamine oxidase B	Homo sapiens	84-108
8489205-11	1993	The overall safety and benefits of lazabemide observed in this short-term study justify further long-term investigations to determine if this monoamine oxidase type B inhibitor can slow the clinical progression of Parkinson"s disease.	lazabemide	35-45	monoamine oxidase B	Homo sapiens	142-166
1668212-1	1991	Some central effects of Ro 19-6327--a new MAO-B inhibitor--were studied in mice and rats.	lazabemide	24-34	monoamine oxidase B	Mus musculus	42-47
1578281-3	1992	Here we describe how reversible and selective inhibitors of MAO-A and MAO-B [Ro 41-1049 and Ro 19-6327 (lazabemide), respectively] can be used, as tritiated radioligands, to map the distribution and abundance of the enzymes in microscopic regions of the rat CNS and peripheral organs, and human brain by quantitative enzyme radioautography.	lazabemide	104-114	monoamine oxidase A	Rattus norvegicus	60-65
1578281-3	1992	Here we describe how reversible and selective inhibitors of MAO-A and MAO-B [Ro 41-1049 and Ro 19-6327 (lazabemide), respectively] can be used, as tritiated radioligands, to map the distribution and abundance of the enzymes in microscopic regions of the rat CNS and peripheral organs, and human brain by quantitative enzyme radioautography.	lazabemide	104-114	monoamine oxidase B	Rattus norvegicus	70-75
1906004-0	1991	Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327.	lazabemide	164-174	monoamine oxidase B	Homo sapiens	56-61
1904879-5	1991	The method was applied to the measurement of the dose-response curve of a reversible MAO-B inhibitor (Ro 19-6327).	lazabemide	102-112	monoamine oxidase B	Homo sapiens	85-90
2089114-5	1990	These effects were absent with the highly selective MAO-B inhibitor Ro 19-6327.	lazabemide	68-78	monoamine oxidase B	Rattus norvegicus	52-57
2380287-0	1990	Determination of the monoamine oxidase B inhibitor Ro 19-6327 in plasma by high-performance liquid chromatography using precolumn derivatization with fluorescamine and fluorescence detection.	lazabemide	51-61	monoamine oxidase B	Homo sapiens	21-40
2380287-1	1990	A specific high-performance liquid chromatographic (HPLC) method using precolumn derivatization and fluorescence detection was developed for the determination of the monoamine oxidase B inhibitor Ro 19-6327 in human plasma.	lazabemide	196-206	monoamine oxidase B	Homo sapiens	166-185
34641548-2	2021	Compounds NEA3 and NEA1 exhibited a more potent MAO-B inhibition (IC50 value = 0.0092 and 0.016 microM, respectively) than the standards (IC50 value = 0.11 and 0.14 microM, respectively, for lazabemide and pargyline).	lazabemide	191-201	monoamine oxidase B	Homo sapiens	48-53
2122653-0	1990	Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.	lazabemide	0-10	monoamine oxidase B	Homo sapiens	106-111
3126263-7	1988	The covalent linkage to membranes of unlabelled Ro 16-6491 and Ro 19-6327 (a selective and reversible MAO-B inhibitor closely related to Ro 16-6491) after the addition of NaBH3CN at pH 4.5 irreversibly inactivated MAO-B activity whereas MAO-A activity was unaffected.	lazabemide	63-73	monoamine oxidase B	Homo sapiens	102-107
3126263-7	1988	The covalent linkage to membranes of unlabelled Ro 16-6491 and Ro 19-6327 (a selective and reversible MAO-B inhibitor closely related to Ro 16-6491) after the addition of NaBH3CN at pH 4.5 irreversibly inactivated MAO-B activity whereas MAO-A activity was unaffected.	lazabemide	63-73	monoamine oxidase B	Homo sapiens	214-219
3126263-7	1988	The covalent linkage to membranes of unlabelled Ro 16-6491 and Ro 19-6327 (a selective and reversible MAO-B inhibitor closely related to Ro 16-6491) after the addition of NaBH3CN at pH 4.5 irreversibly inactivated MAO-B activity whereas MAO-A activity was unaffected.	lazabemide	63-73	monoamine oxidase A	Homo sapiens	237-242
32646880-12	2021	18F-SMBT-1 binding was completely displaced with reversible MAO-B inhibitor lazabemide, demonstrating the high selectivity of 18F-SMBT-1 for MAO-B.	lazabemide	76-86	monoamine oxidase B	Mus musculus	60-65
32646880-12	2021	18F-SMBT-1 binding was completely displaced with reversible MAO-B inhibitor lazabemide, demonstrating the high selectivity of 18F-SMBT-1 for MAO-B.	lazabemide	76-86	monoamine oxidase B	Mus musculus	141-146